These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 15566310

  • 1. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
    Serradji N, Martin M, Bensaid O, Cisternino S, Rousselle C, Dereuddre-Bosquet N, Huet J, Redeuilh C, Lamouri A, Dong CZ, Clayette P, Scherrmann JM, Dormont D, Heymans F.
    J Med Chem; 2004 Dec 02; 47(25):6410-9. PubMed ID: 15566310
    [Abstract] [Full Text] [Related]

  • 2. Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.
    Serradji N, Bensaid O, Martin M, Sallem W, Dereuddre-Bosquet N, Benmehdi H, Redeuilh C, Lamouri A, Dive G, Clayette P, Heymans F.
    Bioorg Med Chem; 2006 Dec 01; 14(23):8109-25. PubMed ID: 16893650
    [Abstract] [Full Text] [Related]

  • 3. Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity.
    Sallem W, Serradji N, Dereuddre-Bosquet N, Dive G, Clayette P, Heymans F.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7999-8013. PubMed ID: 16908170
    [Abstract] [Full Text] [Related]

  • 4. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
    Serradji N, Bensaid O, Martin M, Kan E, Dereuddre-Bosquet N, Redeuilh C, Huet J, Heymans F, Lamouri A, Clayette P, Dong CZ, Dormont D, Godfroid JJ.
    J Med Chem; 2000 Jun 01; 43(11):2149-54. PubMed ID: 10841793
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E, Merlos M, Giral M, Balsa D, García-Rafanell J, Forn J.
    J Med Chem; 1996 Jan 19; 39(2):487-93. PubMed ID: 8558517
    [Abstract] [Full Text] [Related]

  • 6. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan 19; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives.
    Fukushi H, Mabuchi H, Itoh K, Terashita Z, Nishikawa K, Sugihara H.
    Chem Pharm Bull (Tokyo); 1994 Mar 19; 42(3):541-50. PubMed ID: 8004699
    [Abstract] [Full Text] [Related]

  • 8. [PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP, Schmidt B, Ostermann G.
    Pharmazie; 1992 Mar 19; 47(3):172-4. PubMed ID: 1615020
    [Abstract] [Full Text] [Related]

  • 9. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E, Heymans F, Redeuilh C, Batt JP, Massicot F, Blavet N, Braquet P, Godfroid JJ.
    J Lipid Mediat; 1992 Feb 19; 5(1):23-40. PubMed ID: 1449553
    [Abstract] [Full Text] [Related]

  • 10. [Antiretroviral ant anti-inflammatory properties of a novel platelet activation factor antagonist, PMS-601].
    Martin M, Serradji N, Dereuddre-Bosquet N, Bensaïd O, Fichet G, Lamouri A, Heymans F, Clayette P, Godfroid JJ, Dormont D.
    Pathol Biol (Paris); 2000 Jun 19; 48(5):513-9. PubMed ID: 10949851
    [Abstract] [Full Text] [Related]

  • 11. Platelet activating factor induces blood brain barrier permeability alteration in vitro.
    Fang W, Geng X, Deng Y, Li Y, Shang E, Cen J, Lv P.
    J Neuroimmunol; 2011 Jan 19; 230(1-2):42-7. PubMed ID: 20870297
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
    Fukushi H, Mabuchi H, Terashita Z, Nishikawa K, Sugihara H.
    Chem Pharm Bull (Tokyo); 1994 Mar 19; 42(3):551-9. PubMed ID: 8004700
    [Abstract] [Full Text] [Related]

  • 13. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
    Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, De Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, Novellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campiani G.
    J Med Chem; 2005 Nov 17; 48(23):7153-65. PubMed ID: 16279773
    [Abstract] [Full Text] [Related]

  • 14. Heterobiaryl human immunodeficiency virus entry inhibitors.
    Lu RJ, Tucker JA, Pickens J, Ma YA, Zinevitch T, Kirichenko O, Konoplev V, Kuznetsova S, Sviridov S, Brahmachary E, Khasanov A, Mikel C, Yang Y, Liu C, Wang J, Freel S, Fisher S, Sullivan A, Zhou J, Stanfield-Oakley S, Baker B, Sailstad J, Greenberg M, Bolognesi D, Bray B, Koszalka B, Jeffs P, Jeffries C, Chucholowski A, Sexton C.
    J Med Chem; 2009 Jul 23; 52(14):4481-7. PubMed ID: 19534463
    [Abstract] [Full Text] [Related]

  • 15. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
    Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, Strizki JM, Baroudy BM, Cox K, Lachowicz J, Varty G, Watkins R.
    J Med Chem; 2004 May 06; 47(10):2405-8. PubMed ID: 15115380
    [Abstract] [Full Text] [Related]

  • 16. (Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
    Carceller E, Almansa C, Merlos M, Giral M, Bartrolí J, García-Rafanell J, Forn J.
    J Med Chem; 1992 Oct 30; 35(22):4118-34. PubMed ID: 1433215
    [Abstract] [Full Text] [Related]

  • 17. Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
    Lamouri A, Heymans F, Tavet F, Dive G, Batt JP, Blavet N, Braquet P, Godfroid JJ.
    J Med Chem; 1993 Apr 16; 36(8):990-1000. PubMed ID: 8478911
    [Abstract] [Full Text] [Related]

  • 18. Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
    Lu RJ, Tucker JA, Zinevitch T, Kirichenko O, Konoplev V, Kuznetsova S, Sviridov S, Pickens J, Tandel S, Brahmachary E, Yang Y, Wang J, Freel S, Fisher S, Sullivan A, Zhou J, Stanfield-Oakley S, Greenberg M, Bolognesi D, Bray B, Koszalka B, Jeffs P, Khasanov A, Ma YA, Jeffries C, Liu C, Proskurina T, Zhu T, Chucholowski A, Li R, Sexton C.
    J Med Chem; 2007 Dec 27; 50(26):6535-44. PubMed ID: 18052117
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
    Aquaro S, Svicher V, Schols D, Pollicita M, Antinori A, Balzarini J, Perno CF.
    J Leukoc Biol; 2006 Nov 27; 80(5):1103-10. PubMed ID: 16931601
    [Abstract] [Full Text] [Related]

  • 20. Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion.
    Duan M, Peckham J, Edelstein M, Ferris R, Kazmierski WM, Spaltenstein A, Wheelan P, Xiong Z.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7397-400. PubMed ID: 21035337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.